Clinical Trial Update: Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating topical cyclosporine 0.010% for Atopic Keratoconjunctivitis reports efficacy and safety results; the trial completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Keratoconjunctivitis

Drugs mentioned

• Cyclosporine 0.010% (topical) (cyclosporine)

Snippet

Sponsor: Allergan | Conditions: Atopic Conjunctivitis | Phase 3 | Status: COMPLETED | Results posted: 2012-11-05